iRadimed Corporation (NASDAQ:IRMD) Stock Has Average Price Target of $120.00

Posted by Brian Himes on Oct 2nd, 2026

Shares of iRadimed Corporation (NASDAQ:IRMD – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $120.00.

IRMD has been the topic of a number of recent analyst reports. Weiss Ratings raised iRadimed from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, September 9th. Needham & Company LLC initiated coverage on shares of iRadimed in a research report on Tuesday, September 22nd. They set a “hold” rating for the company. Finally, Wall Street Zen lowered shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

View Our Latest Stock Report on IRMD

Insiders Place Their Bets

In related news, Director Monty K. Allen sold 1,419 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the transaction, the director owned 19,581 shares in the company, valued at $1,691,994.21. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.60% of the stock is owned by corporate insiders.

Institutional Trading of iRadimed

A number of large investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC bought a new position in shares of iRadimed in the 2nd quarter worth about $28,000. NewEdge Advisors LLC boosted its position in shares of iRadimed by 46.9% during the 2nd quarter. NewEdge Advisors LLC now owns 25,254 shares of the medical equipment provider’s stock valued at $2,413,000 after purchasing an additional 8,063 shares in the last quarter. IFP Advisors Inc boosted its position in shares of iRadimed by 264.7% during the 2nd quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 413 shares in the last quarter. Punch & Associates Investment Management Inc. acquired a new stake in iRadimed during the second quarter worth approximately $1,911,000. Finally, Bank of America Corp DE acquired a new stake in iRadimed during the second quarter worth approximately $1,834,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Stock Down 1.1%

NASDAQ IRMD opened at $85.30 on Tuesday. iRadimed has a twelve month low of $69.47 and a twelve month high of $107.90. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 47.65 and a beta of 0.91. The business’s fifty day moving average is $87.35 and its 200 day moving average is $91.32.

iRadimed (NASDAQ:IRMD – Get Free Report) last issued its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, research analysts anticipate that iRadimed will post 1.98 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were given a dividend of $0.20 per share. The ex-dividend date was Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is 44.69%.

About iRadimed

(Get Free Report)

iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on equipment that enables clinicians to provide continuous care and monitor patients safely while they are undergoing MRI procedures, where conventional medical devices may pose safety or compatibility challenges.

Its product portfolio includes the MRidium MRI-compatible infusion pump systems, which are designed to deliver intravenous medications and fluids during MRI examinations, as well as MRI-compatible patient monitoring systems and related accessories.